Vivace Therapeutics reported preclinical efficacy for VT-3989, a TEAD inhibitor, in in vitro and in vivo models of aggressive NF2‑deficient tumors including meningioma. Company data show tumor growth suppression in animal models and support the agent’s continued development across advanced solid tumors. Vivace positions VT-3989 for early clinical testing as a targeted approach for NF2 pathway–driven malignancies.